secwatch.observer — SEC 8-K summary
======================================

Issuer:     LISATA THERAPEUTICS, INC. (LSTA)
CIK:        0000320017
Form:       8-K
Filed at:   2025-05-08T23:59:59+00:00
Accession:  0000320017-25-000028
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lisata Q1 net loss $4.7M; cash $25.8M; ASCEND Cohort B oral at ESMO-GI Jul 2025
-------------------------------------------------------------------------------

- Net loss $4.7M for Q1 2025, vs $5.4M in Q1 2024; operating expenses down 11% to $5.8M.
- Cash, equivalents, and marketable securities $25.8M as of Mar 31, 2025; runway into Q3 2026.
- Cohort B of ASCEND trial (mPDAC) accepted for oral presentation at ESMO-GI July 2025; final analysis pending.
- BOLSTER trial in first-line cholangiocarcinoma fully enrolled; topline data anticipated mid-2025.
- Qilu's Phase 2 certepetide trial in China complete; Phase 3 start triggers $10M milestone payment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/320017/000032001725000028/0000320017-25-000028-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/320017/000032001725000028/clbs-20250508.htm
  HTML page:      https://secwatch.observer/filing/0000320017-25-000028

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer